First Republic Investment Management, Inc. Clovis Oncology, Inc. Transaction History

First Republic Investment Management, Inc.

$34.7 Billion
Q3 2023

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$0.63 - $2.96 $5,295 - $24,878	8,405 Added 61.82%	22,000 $40,000
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $19,440 - $42,688	13,595 New	13,595 $27,000
Q4 2021 Feb 09, 2022	SELL	$2.7 - $4.76 $117,409 - $206,988	-43,485 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$4.06 - $5.8 $8,119 - $11,600	2,000 Added 4.82%	43,485 $194,000
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $208,254 - $292,469	41,485 New	41,485 $241,000
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $95,574 - $205,455	-19,870 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $82,063 - $127,366	19,870 New	19,870 $95,000
Q1 2018 May 10, 2018	SELL	$50.12 - $67.72 $159,682 - $215,755	-3,186 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$57.69 - $84.58 $8,307 - $12,179	144 Added 4.73%	3,186 $217,000
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $204,331 - $257,992	3,042	3,042 $251,000

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.

Account